TEHRAN – In past Iranian calendar years that ended March 20th, a total of 26 patients (ages 9-50) of hemophilia have lost their lives from the lack of drugs caused by sanctions, according to the chairman of the Iranian Hemophilia Association’s board of directors.
The Food and Drug Administration (FDA) must do its best to distribute the medications patients need fairly.
Officials made a statement on Tuesday on World Blood Disease Day, which is observed on April 17th each year.
Hemophilia is a hereditary bleeding disorder that usually causes the blood to not clot properly and affects most men. It is estimated that it occurs in about one animal per birth of 5,000 men. Hemophilia patients have low levels of proteins called coagulation factors that help to stop bleeding. This disease can cause spontaneous bleeding within the joint, leading to chronic joint disease and pain, leading to skin, head and brain bleeding that can cause seizures and paralysis.
It can also lead to injuries and excessive bleeding after surgery. Death can occur if bleeding cannot stop or occurs in a critical organ, such as the brain.
Authorities also said about 14,000 hemophilia patients are registered with the country. Deficiencies in factors 8 and 9 hemophilia drugs are very pronounced in countries that risk patients’ lives.
Apart from the drug shortage, there are several issues with the distribution system due to the lack of careful surveillance. Therefore, he noted that the drug is not fully and appropriately available to hemophilia patients, causing acute problems, including disorders.
World Hemophilia Day aims to promote the importance of taking coordinated and coordinated actions to achieve the vision of global hematology (WFH) of “treatment for all.”
This year’s theme is “Access to everyone: Women and girls also bleeding.” Today, women and girls with hemorrhagic disorder (WGBD) are still undiagnosed and there is a lack of service. The global bleeding disorder community has the power and responsibility to change this. Through recognition, diagnosis, treatment and care, the quality of life for women and girls will improve and the bleeding disorder community will be stronger.
Medicine imports crisis after sanctions
In November, a senior FDA official revealed that European Union sanctions had a major impact on Iran’s drug imports, making patients particularly vulnerable to patients with important health needs.
The government is currently investigating alternative routes to ensure a stable flow of essential medical supplies to the country.
At the Nursing Equipment Exhibition in Tehran by FDA Deputy Director Fereshte Mirzazadeh, we provided an update on the measures Iran is taking to combat these obstacles.
“We are working to open a special air corridor and work with international companies to enhance domestic production,” Mirzazadeh said. “These strategies are essential to ensure that we have the medical supplies needed for our population.”
mt/mg